ABSTRACT
Magnetic Resonance imaging based Electrical Properties Tomography (MR-EPT) is a non-invasive technique that measures the electrical properties (EPs) of biological tissues. In this work, we present and numerically investigate the performance of an unrolled, physics-assisted method for 2D MR-EPT reconstructions, where a cascade of Convolutional Neural Networks is used to compute the contrast update. Each network takes in input the EPs and the gradient descent direction (encoding the physics underlying the adopted scattering model) and returns as output the updated contrast function. The network is trained and tested in silico using 2D slices of realistic brain models at 128 MHz. Results show the capability of the proposed procedure to reconstruct EPs maps with quality comparable to that of the popular Contrast Source Inversion-EPT, while significantly reducing the computational time.
ABSTRACT
At ultrahigh field strengths images of the body are hampered by B1 -field inhomogeneities. These present themselves as inhomogeneous signal intensity and contrast, which is regarded as a "bias field" to the ideal image. Current bias field correction methods, such as the N4 algorithm, assume a low frequency bias field, which is not sufficiently valid for T2w images at 7 T. In this work we propose a deep learning based bias field correction method to address this issue for T2w prostate images at 7 T. By combining simulated B1 -field distributions of a multi-transmit setup at 7 T with T2w prostate images at 1.5 T, we generated artificial 7 T images for which the homogeneous counterpart was available. Using these paired data, we trained a neural network to correct the bias field. We predicted either a homogeneous image (t-Image neural network) or the bias field (t-Biasf neural network). In addition, we experimented with the single-channel images of the receive array and the corresponding sum of magnitudes of this array as the input image. Testing was carried out on four datasets: the test split of the synthetic training dataset, volunteer and patient images at 7 T, and patient images at 3 T. For the test split, the performance was evaluated using the structural similarity index measure, Wasserstein distance, and root mean squared error. For all other test data, the features Homogeneity and Energy derived from the gray level co-occurrence matrix (GLCM) were used to quantify the improvement. For each test dataset, the proposed method was compared with the current gold standard: the N4 algorithm. Additionally, a questionnaire was filled out by two clinical experts to assess the homogeneity and contrast preservation of the 7 T datasets. All four proposed neural networks were able to substantially reduce the B1 -field induced inhomogeneities in T2w 7 T prostate images. By visual inspection, the images clearly look more homogeneous, which is confirmed by the increase in Homogeneity and Energy in the GLCM, and the questionnaire scores from two clinical experts. Occasionally, changes in contrast within the prostate were observed, although much less for the t-Biasf network than for the t-Image network. Further, results on the 3 T dataset demonstrate that the proposed learning based approach is on par with the N4 algorithm. The results demonstrate that the trained networks were capable of reducing the B1 -field induced inhomogeneities for prostate imaging at 7 T. The quantitative evaluation showed that all proposed learning based correction techniques outperformed the N4 algorithm. Of the investigated methods, the single-channel t-Biasf neural network proves most reliable for bias field correction.
Subject(s)
Deep Learning , Prostate , Male , Humans , Prostate/diagnostic imaging , Neural Networks, Computer , Algorithms , Image Processing, Computer-Assisted/methodsABSTRACT
In the last 5 years, deep learning applications for radiotherapy have undergone great development. An advantage of radiotherapy over radiological applications is that data in radiotherapy are well structured, standardized, and annotated. Furthermore, there is much to be gained in automating the current laborious workflows in radiotherapy. After the initial peak in the belief in deep learning, researchers have also identified fundamental weaknesses of deep learning. The basic assumption in deep learning is that the training and test data originate from the same data generating process. This is not always clear-cut in clinical practice, eg, data acquired with 2 different scanners of different vendors might not originate from the same data generating process. Furthermore, it is important to realize residual uncertainties remain even if test data arise from the same data generating process as the training data. As deep learning applications are being introduced in clinical radiotherapy workflows, a deep learning model must express to a user when a prediction exceeds a certain uncertainty threshold. The literature on uncertainty assessment for deep learning applications in radiotherapy is still in its infancy; however, quite a body of literature exists on the validity and uncertainty of deep learning models for computer vision applications. This paper tries to explain these general concepts to the radiotherapy community. Concepts of epistemic and aleatoric uncertainties and techniques to model them in deep learning are described in detail. It is discussed how they can be applied to maximize confidence in automated deep learning-driven workflows. Their usage is demonstrated in 3 examples from radiotherapy literature on deep learning applications, ie, dose prediction, synthetic CT generation, and contouring. In the final part, some of the key elements to ensure confidence and automatic alerting that are still missing are discussed. State-of-the-art automatic solutions for checking within-distribution vs out-of-distribution test samples are discussed. However, these methodologies are still immature, and strict QA protocols and close human supervision will still be needed. Nevertheless, deep learning models offer already much value for radiotherapy.
Subject(s)
Deep Learning , Humans , Radiotherapy Planning, Computer-Assisted/methods , Software , UncertaintyABSTRACT
The human cerebellum is involved in a wide array of functions, ranging from motor control to cognitive control, and as such is of great neuroscientific interest. However, its function is underexplored in vivo, due to its small size, its dense structure and its placement at the bottom of the brain, where transmit and receive fields are suboptimal. In this study, we combined two dense coil arrays of 16 small surface receive elements each with a transmit array of three antenna elements to improve BOLD sensitivity in the human cerebellum at 7 T. Our results showed improved B1+ and SNR close to the surface as well as g-factor gains compared with a commercial coil designed for whole-head imaging. This resulted in improved signal stability and large gains in the spatial extent of the activation close to the surface (<3.5 cm), while good performance was retained deeper in the cerebellum. Modulating the phase of the transmit elements of the head coil to constructively interfere in the cerebellum improved the B1+ , resulting in a temporal SNR gain. Overall, our results show that a dedicated transmit array along with the SNR gains of surface coil arrays can improve cerebellar imaging, at the cost of a decreased field of view and increased signal inhomogeneity.
Subject(s)
Cerebellum/diagnostic imaging , Magnetic Resonance Imaging/instrumentation , Humans , Oxygen/blood , Radio Waves , Signal-To-Noise RatioABSTRACT
PURPOSE: To investigate inter-subject variability of B1+ , SAR and temperature rise in a database of human models using a local transmit array for 7 T cardiac imaging. METHODS: Dixon images were acquired of 14 subjects and segmented in dielectric models with an eight-channel local transmit array positioned around the torso for cardiac imaging. EM simulations were done to calculate SAR distributions. Based on the SAR distributions, temperature simulations were performed for exposure times of 6 min and 30 min. Peak local SAR and temperature rise levels were calculated for different RF shim settings. A statistical analysis of the resulting peak local SAR and temperature rise levels was performed to arrive at safe power limits. RESULTS: For RF shim vectors with random phase and uniformly distributed power, a safe average power limit of 35.7 W was determined (first level controlled mode). When RF amplitude and phase shimming was performed on the heart, a safe average power limit of 35.0 W was found. According to Pennes' model, our numerical study suggests a very low probability of exceeding the absolute local temperature limit of 40 °C for a total exposure time of 6 min and a peak local SAR of 20 W/kg. For a 30 min exposure time at 20 W/kg, it was shown that the absolute temperature limit can be exceeded in the case where perfusion does not change with temperature. CONCLUSION: Safe power constraints were found for 7 T cardiac imaging with an eight-channel local transmit array, while considering the inter-subject variability of B1+ , SAR and temperature rise.
Subject(s)
Absorption, Radiation , Heart/diagnostic imaging , Magnetic Resonance Imaging , Temperature , Adult , Computer Simulation , Electromagnetic Fields , Humans , Middle Aged , Models, BiologicalABSTRACT
In the radiofrequency (RF) range, the electrical properties of tissues (EPs: conductivity and permittivity) are modulated by the ionic and water content, which change for pathological conditions. Information on tissues EPs can be used e.g. in oncology as a biomarker. The inability of MR-Electrical Properties Tomography techniques (MR-EPT) to accurately reconstruct tissue EPs by relating MR measurements of the transmit RF field to the EPs limits their clinical applicability. Instead of employing electromagnetic models posing strict requirements on the measured MRI quantities, we propose a data driven approach where the electrical properties reconstruction problem can be casted as a supervised deep learning task (DL-EPT). DL-EPT reconstructions for simulations and MR measurements at 3 Tesla on phantoms and human brains using a conditional generative adversarial network demonstrate high quality EPs reconstructions and greatly improved precision compared to conventional MR-EPT. The supervised learning approach leverages the strength of electromagnetic simulations, allowing circumvention of inaccessible MR electromagnetic quantities. Since DL-EPT is more noise-robust than MR-EPT, the requirements for MR acquisitions can be relaxed. This could be a major step forward to turn electrical properties tomography into a reliable biomarker where pathological conditions can be revealed and characterized by abnormalities in tissue electrical properties.
ABSTRACT
PURPOSE: For ultrahigh field (UHF) MRI, the expected local specific absorption rate (SAR) distribution is usually calculated by numerical simulations using a limited number of generic body models and adding a safety margin to take into account intersubject variability. Assessment of this variability with a large model database would be desirable. In this study, a procedure to create such a database with accurate subject-specific models is presented. Using 23 models, intersubject variability is investigated for prostate imaging at 7T with an 8-channel fractionated dipole antenna array with 16 receive loops. METHOD: From Dixon images of a volunteer acquired at 1.5T with a mockup array in place, an accurate dielectric model is built. Following this procedure, 23 subject-specific models for local SAR assessment at 7T were created enabling an extensive analysis of the intersubject B1+ and peak local SAR variability. RESULTS: For the investigated setup, the maximum possible peak local SAR ranges from 2.6 to 4.6 W/kg for 8 × 1 W input power. The expected peak local SAR values represent a Gaussian distribution (µ/σ=2.29/0.29 W/kg) with realistic prostate-shimmed phase settings and a gamma distribution Γ(24,0.09) with multidimensional radiofrequency pulses. Prostate-shimmed phase settings are similar for all models. Using 1 generic phase setting, average B1+ reduction is 7%. Using only 1 model, the required safety margin for intersubject variability is 1.6 to 1.8. CONCLUSION: The presented procedure allows for the creation of a customized model database. The results provide valuable insights into B1+ and local SAR variability. Recommended power thresholds per channel are 3.1 W with phase shimming on prostate or 2.6 W for multidimensional pulses.
Subject(s)
Image Processing, Computer-Assisted/methods , Magnetic Resonance Imaging , Phantoms, Imaging , Prostate/diagnostic imaging , Adult , Algorithms , Computer Simulation , Humans , Imaging, Three-Dimensional , Male , Middle Aged , Models, Theoretical , Radio Waves , Reproducibility of ResultsABSTRACT
BACKGROUND: (18)Fluor-deoxy-glucose PET-scanning of glycolytic metabolism is being used for staging in many tumors however its impact on prognosis has never been studied in breast cancer. METHODS: Glycolytic and hypoxic markers: glucose transporter (GLUT1), carbonic anhydrase IX (CAIX), monocarboxylate transporter 1 and 4 (MCT1, 4), MCT accessory protein basigin and lactate-dehydrogenase A (LDH-A) were assessed by immunohistochemistry in two cohorts of breast cancer comprising 643 node-negative and 127 triple negative breast cancers (TNBC) respectively. RESULTS: In the 643 node-negative breast tumor cohort with a median follow-up of 124 months, TNBC were the most glycolytic (≈70%), followed by Her-2 (≈50%) and RH-positive cancers (≈30%). Tumoral MCT4 staining (without stromal staining) was a strong independent prognostic factor for metastasis-free survival (HR=0.47, P=0.02) and overall-survival (HR=0.38, P=0.002). These results were confirmed in the independent cohort of 127 cancer patients. CONCLUSION: Glycolytic markers are expressed in all breast tumors with highest expression occurring in TNBC. MCT4, the hypoxia-inducible lactate/H(+) symporter demonstrated the strongest deleterious impact on survival. We propose that MCT4 serves as a new prognostic factor in node-negative breast cancer and can perhaps act soon as a theranostic factor considering the current pharmacological development of MCT4 inhibitors.
Subject(s)
Biomarkers, Tumor/metabolism , Breast Neoplasms/metabolism , Monocarboxylic Acid Transporters/metabolism , Muscle Proteins/metabolism , Triple Negative Breast Neoplasms/metabolism , Triple Negative Breast Neoplasms/mortality , Adult , Aged , Aged, 80 and over , Antigens, Neoplasm/metabolism , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Carbonic Anhydrase IX , Carbonic Anhydrases/metabolism , Female , Glucose Transporter Type 1/metabolism , Glycolysis , Humans , Isoenzymes/metabolism , L-Lactate Dehydrogenase/metabolism , Lactate Dehydrogenase 5 , Middle Aged , Positron-Emission Tomography/methods , Predictive Value of Tests , Prognosis , Triple Negative Breast Neoplasms/pathologyABSTRACT
PURPOSE: Currently, radical mastectomy represents the gold standard for ipsilateral breast cancer recurrence. However, we already showed that a second conservative treatment was feasible combining lumpectomy plus low-dose rate interstitial brachytherapy. In this study, we reported the preliminary results of a second conservative treatment using a high-dose rate brachytherapy. PATIENTS AND METHODS: From June 2005 to July 2009, 42 patients presenting with an ipsilateral breast cancer recurrence underwent a second conservative treatment. Plastic tubes were implanted intra-operatively at the time of the lumpectomy. After a post-implant CT scan, a total dose of 34 Gy in 10 fractions over 5 consecutive days was delivered through an ambulatory procedure. The toxicity evaluation used the Common Terminology Criteria for Adverse Events v3.0. RESULTS: The median follow-up was 21 months (6-50 months), median age at the time of the local recurrence was 65 years (30-85 years). The median delay between the primary and the recurrence was 11 years (1-35 years). The location of the recurrence was in the tumor bed for 22 patients (52.4%), in the same quadrant for 14 patients (33.3%) and unknown for six patients (14.3%). The median tumor size of the recurrence was 12 mm (2-30 mm). The median number of plastic tubes and plans were nine (5-12) and two (1-3) respectively. The median CTV was 68 cm(3) (31.2-146 cm(3)). The rate of second local control was 97%. Twenty-two patients (60%) experienced complications. The most frequent side effect consisted in cutaneous and sub-cutaneous fibrosis (72% of all the observed complications). CONCLUSION: A second conservative treatment for ipsilateral breast cancer recurrence using high-dose rate brachytherapy appears feasible leading to encouraging results in terms of second local control with an acceptable toxicity. Considering that a non-inferiority randomized trial comparing mastectomy versus second conservative treatment could be difficult to perform, what proof level will be necessary to achieve in order to change the medical procedures?
Subject(s)
Brachytherapy/methods , Breast Neoplasms/radiotherapy , Neoplasm Recurrence, Local/radiotherapy , Adult , Aged , Aged, 80 and over , Breast Neoplasms/diagnostic imaging , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Female , Follow-Up Studies , Humans , Mastectomy/methods , Middle Aged , Neoplasm Recurrence, Local/diagnostic imaging , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/surgery , Radiography , Reoperation/methods , Retrospective Studies , Tumor BurdenABSTRACT
OBJECTIVE: To determine whether MRI assesses the size of ductal carcinomas in situ (DCIS) more accurately than mammography, using the histopathological dimension of the surgical specimen as the reference measurement. MATERIALS AND METHODS: This single-center prospective study conducted from March 2007 to July 2008 at the Antoine-Lacassagne Cancer Treatment Center (Nice, France) included 33 patients with a histologically proven DCIS by needle biopsy, who all underwent clinical examination, mammography, and MRI interpreted by an experienced radiologist. All patients underwent surgery at our institution. The greatest dimensions of the DCIS determined by the two imaging modalities were compared with the histopathological dimension ascertained on the surgical specimen. The study was approved by the local Ethical Research Committee and was authorized by the French National Health Agency (AFSSAPS). RESULTS: The mean age of the 33 patients was 59.7 years (± 10.3). Three patients had a palpable mass at clinical breast examination; 82% underwent conservative surgical therapy rather than radical breast surgery (mastectomy); 6% required repeat surgery. MRI detected 97% of the lesions. Non-mass-like enhancement was noted for 78% of the patients. In over 50% of the cases, distribution of the DCIS was ductal or segmental and the kinetic enhancement curve was persistent. Lesion size was correctly estimated (± 5 mm), under-estimated (<5mm), or over-estimated (>5mm), respectively, by MRI in 60%, 19% and 21% of cases and by mammography in 38%, 31% and 31% (p = 0.05). Mean lesion size was 25.6mm at histopathology, 28.1mm at MRI, and 27.2mm on mammography (nonsignificant difference). The correlation coefficient between histopathological measurement and MRI was 0.831 versus 0.674 between histopathology and mammography. The correlation coefficient increased with the nuclear grade of the DCIS on mammography; this coefficient also increased as the mammographic breast density decreased. CONCLUSION: MRI appears to assess the size of DCIS better than mammography by limiting the number of under- and over-estimations compared to histopathology findings.
Subject(s)
Breast Neoplasms/pathology , Carcinoma, Intraductal, Noninfiltrating/pathology , Magnetic Resonance Imaging/methods , Female , Humans , Middle Aged , Prospective Studies , Reproducibility of Results , Sensitivity and SpecificityABSTRACT
BACKGROUND: We analysed whether the level of human epidermal growth factor receptor-2 (HER-2) amplification significantly influenced either pathological complete response (pCR) or recurrence-free survival (RFS) and overall survival (OS) after trastuzumab-based neoadjuvant therapy. METHODS: In all, 99 patients with an HER-2-amplified breast tumour treated with trastuzumab-based neoadjuvant therapy were included. Tumours were classified as low amplified (LA; 6-10 signals per nuclei) or highly amplified (HA; >10 signals). Pathological response was assessed according to Chevallier's classification (pCR was defined as grade 1 or 2). Median follow-up lasted 46 months (6-83). Cox uni- and multivariate analyses were performed. RESULTS: In all, 33 tumour samples were LA and 66 were HA. The pCR in HA tumours was significantly higher than in LA tumours (55% vs 24%, P=0.005), whereas no association was found between the pCR rate and tumour stage, grade or hormone receptor status. In multivariate analysis, the pathological nodal status (P=0.005) and adjuvant trastuzumab (P=0.037) were independently associated with RFS, whereas the level of HER-2 amplification nearly reached statistical significance (P=0.057). There was no significant difference between LA and HA tumours for OS (P=0.22, log-rank). CONCLUSION: The level of HER-2 gene amplification significantly influenced pCR but not RFS or OS in non-metastatic breast cancer treated with trastuzumab-based neoadjuvant therapy. However, RFS in patients with HA tumours tended to be shorter.
Subject(s)
Antibodies, Monoclonal/administration & dosage , Breast Neoplasms/drug therapy , Breast Neoplasms/genetics , Genes, erbB-2 , Adult , Aged , Antibodies, Monoclonal, Humanized , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Disease-Free Survival , Female , Gene Amplification , Humans , Middle Aged , Neoadjuvant Therapy , Remission Induction , TrastuzumabABSTRACT
OBJECTIVES: Papillary microcarcinoma (PMC) is one of the most frequent pathological forms of thyroid cancer Here, we describe the circumstances of diagnosis and the clinical and pathological characteristics of this tumour We also analyze the therapeutic management and compare it with the recent published guidelines. METHODS: Between 2000 and 2006, a total of 230 patients with a PMC of the thyroid gland were included in this retrospective study. We have investigated the correlations between some pathological parameters (plurifocality, lymph node invasion...) and several factors (age, gender, tumour size...). RESULTS: The diagnosis of PMC was suspected in the preoperative period in 15% of the patients, and was confirmed intraoperatively by the pathologist in 42% of the cases. Plurifocal or bilateral PMC were discovered in respectively 30 and 17% of the patients. The rate of lymph node invasion in the central neck (level VI) was 26%. An elevated tumor size was correlated with a higher rate of plurifocal or bilateral PMC and of lymph node metastasis (p < 0.05). The indications for postoperative radioiodine therapy were reduced by approxiately 50% in the second part of our study. There were no case of thyroid PMC-related death. CONCLUSIONS: Even for these small tumours, tumour size remains correlated with the tumour aggressiveness. The place of radioiodine therapy in the management of thyroid PMC was progressively reduced because of the good prognosis of this tumour.
Subject(s)
Carcinoma, Papillary/pathology , Carcinoma, Papillary/surgery , Thyroid Neoplasms/pathology , Thyroid Neoplasms/surgery , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Lymph Node Excision , Lymphatic Metastasis , Male , Middle Aged , Retrospective Studies , Thyroidectomy , Young AdultABSTRACT
PURPOSE: Among all the accelerated and partial breast irradiation (APBI) techniques, low then high dose rate, interstitial brachytherapy (HDIB) was the first to be used in this field. This study presents the preliminary clinical and dosimetric results of the APBI using HDIB, performed in Antoine Lacassagne Cancer Center of Nice. PATIENTS AND METHODS: From June 2004 to March 2008, 61 patients (37 primary tumors and 24 second conservative treatments after local recurrence) presenting with T1-2 pN0 non-lobular invasive breast carcinoma, underwent lumpectomy with sentinel lymph node dissection and intraoperative tube placement for HDIB. Dose distribution analysis, using dose-volume histograms, was achieved based on a postoperative CT scan. A comparative dosimetric study was performed between optimized (O) and non-optimized (NO) dose distribution. Then, based on conformal index calculation, a novel index was proposed taking into account not only the conformity but also the homogeneity of HDIB implant. An analysis of dose gradient impact on HDIB biological equivalence dose was also conducted. Statistical analysis used T test confirmed by Wilcoxon test for cohort including less than 30 patients. RESULTS: The comparative dosimetric analysis between O and NO dose distributions shown that conformity indexes (conformal index, conformal number, and D90%) were significantly increased after optimization. Improving conformity leads to increasing hyperdosage volumes (V150% and V200%). A new index named conformity and homogeneity index (CHI) including V150% values, modified the conformal index. A total dose of 34 Gy, delivered through HDIB in 10 fractions over five days was biologically equivalent to 41.93 Gy assuming alpha/beta = 4 Gy and 75.76 Gy if the dose gradient was considered in the calculation. CONCLUSIONS: HDIB is considered as one of the best IPAS technique. HDIB allows dose distribution optimization, skin spearing and accurate clinical target volume definition. Furthermore, HDIB dose gradient could play a key role for breast cancer local control.
Subject(s)
Brachytherapy/methods , Breast Neoplasms/radiotherapy , Aged , Aged, 80 and over , Brachytherapy/adverse effects , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Combined Modality Therapy , Female , Humans , Mastectomy, Segmental , Neoplasm Staging , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted/methods , Skin/pathology , Skin/radiation effectsABSTRACT
BACKGROUND: Treatment of metastatic breast cancer (MBC) remains palliative. Patients with MBC represent a heterogeneous group whose prognosis and outcome may be dependent on host factors. The purpose of the present study was dual: first, to draw up a list of factors easily available in everyday clinical practice requiring no sophisticated or costly methods and second, to provide results from a large cohort of women who underwent diagnostic and treatment at a single institution. PATIENTS AND METHODS: From 1975 to 2005, a total of 1,038 women with MBC during their follow-up were included in this retrospective analysis. Patients were subsequently assigned to five groups according to the period of metastatic diagnosis. RESULTS: It is shown that age at initial diagnosis, hormonal receptor status and site of metastasis are the most relevant prognostic factors for predicting survival from the time of metastastic occurrence. It is also shown that a metastasis-free interval is an easily and immediately available multifactorial prognostic index reflecting the multiparametric variability of the disease. CONCLUSION: These fundamental observations may assist physicians in evaluating the survival potential of patients and in directing them toward the appropriate therapeutic decision.
Subject(s)
Breast Neoplasms/mortality , Breast Neoplasms/pathology , Neoplasms, Hormone-Dependent/mortality , Neoplasms, Hormone-Dependent/pathology , Adult , Age Factors , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Chemotherapy, Adjuvant , Disease-Free Survival , Female , Humans , Kaplan-Meier Estimate , Middle Aged , Neoplasms, Hormone-Dependent/drug therapy , Prognosis , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Retrospective StudiesABSTRACT
To prospectively evaluate a compact portable 10-gauge handheld battery-operated biopsy system for stereotactic biopsy of microcalcifications. The ethics committee of the hospital approved this prospective multicentric study, and informed consent was obtained. Biopsy under stereotactic guidance was performed in 215 patients for 219 lesions consisting of microcalcifications without mass. The feasibility and the tolerance of the procedure were evaluated. The mean weight of the specimen was calculated. In patients with surgical diagnoses, the underestimation rate in biopsy diagnoses of atypical ductal hyperplasia and ductal carcinoma in situ were evaluated. The sampled specimens were separated according to the presence of calcifications on magnified specimen radiographs and to the probe the rotation number in order to evaluate the contribution of each rotation and the contribution of the specimen with and without calcifications on the radiographs. The macrobiopsy was feasible in 98.5% of the patients and was well tolerated in 82% of patients. It identified 4.6% invasive carcinomas, 18.5% ductal carcinomas in situ, 14.8% atypical ductal hyperplasias, 22.2% benign proliferative mastopathies and 39.8% benign non-proliferative mastopathies. The underestimation rate was 26.6% when an atypical ductal hyperplasia was diagnosed at biopsy, and 7.7% when a ductal carcinoma in situ was diagnosed. In the 77 patients with surgical correlation, the accurate diagnosis was obtained in specimens sampled during the first, second, and third in 69%, 9%, and 4% of the biopsies, respectively, and the analysis of specimens without microcalcification had an added value in 8% of patients. The compact portable battery-operated biopsy system can be used successfully for stereotactic biopsy of microcalcifications and constitutes a valid alternative to current systems.
Subject(s)
Biopsy, Needle/instrumentation , Breast Neoplasms/diagnosis , Calcinosis/diagnosis , Breast Neoplasms/pathology , Calcinosis/pathology , Chi-Square Distribution , Diagnosis, Differential , Early Diagnosis , Female , Humans , Prospective Studies , Stereotaxic Techniques , Surveys and Questionnaires , VacuumABSTRACT
BACKGROUND: Occult invasive disease could be found at definitive histology in patients initially diagnosed with large ductal carcinoma in situ (DCIS). Sentinel lymph node (SLN) biopsy is a reliable and minimally invasive procedure providing axillary information and avoiding a second operation in this particular group of patients. The aim of our study was to assess the value of SLN biopsy in patients with large DCIS who are at highest risk for being upstaged to invasive carcinoma. PATIENTS AND METHODS: The study included 195 patients diagnosed with DCIS upon initial core biopsy and undergoing SLN biopsy. Many features were correlated with the presence of unsuspected invasive disease and positive SLN biopsy using univariate and multivariate analyses. RESULTS: Of the 110 patients with pure DCIS, seven patients (6%) had a metastatic lymph node; 31 patients (16%) were found to have invasive disease upon final histology. Univariate analysis of predictors of unsuspected invasive carcinoma showed that patients having a preoperative biopsy that indicated DCIS with microinvasion (DCISM) or large DCIS were at a higher risk of invasive carcinoma after histological examination of the operative specimen. Of the 31 patients who were upstaged to invasive carcinoma at final histology, seven patients (22%) had a positive SLN biopsy. The analysis of predictors of positive SLN in our study shows that diffuse DCIS requiring mastectomy is the main risk factor for SLN metastasis. CONCLUSION: There are no real predictive factors for invasive disease in patients with an initial diagnosis of DCIS or DCISM. Our study supports the value of SLN biopsy in patients with a preoperative DCISM biopsy or patients with a large pure DCIS biopsy requiring mastectomy.
Subject(s)
Breast Neoplasms/pathology , Carcinoma, Ductal/pathology , Adult , Aged , Carcinoma, Ductal/secondary , Female , Humans , Lymph Nodes/pathology , Lymphatic Metastasis/pathology , Middle Aged , Neoplasm Invasiveness/pathology , Predictive Value of Tests , Risk Factors , Sentinel Lymph Node BiopsyABSTRACT
OBJECTIVES: The aim of this work was to report on the clinical, radiological and histological characteristics of ameloblastomas concerning bone structures of the face, rare but not exceptional tumours, and to communicate our experience of their treatment. MATERIAL AND METHODS: The authors reexamined six recent cases of patients presenting with ameloblastoma at the centre Antoine Lacassagne in Nice. The diagnostic context, the treatment and the development of the disease are given in detail, emphasizing the frequency of local relapse of this histologically benign condition. RESULTS: The study of these cases confirmed the benefit of surgical treatment of ameloblastoma. The frequency of local relapse in the cases of close resection, leaving in place micro-foci, justifies enlarged intervention, which is often bone destructive. CONCLUSION: When the continuity of the bone is interrupted, in particular at the level of the mandible, and if the general condition of the patient permits, repair is preferable. In this situation, the procedure of choice is micro-anastomosis of the fibula.
Subject(s)
Ameloblastoma/epidemiology , Ameloblastoma/pathology , Mandibular Neoplasms/epidemiology , Mandibular Neoplasms/pathology , Adult , Aged , Ameloblastoma/surgery , Female , Humans , Male , Mandibular Neoplasms/surgery , Middle Aged , Neoplasm StagingABSTRACT
The development of imaging-guided biopsy techniques has considerably improved the early diagnosis of breast cancers following initial detection by screening. Nevertheless, in a small percentage of cases, histopathologic findings are unsatisfactory owing to false negative errors attributable to operator inexperience or inadequate sample material (this is especially true for microcalcifications with 20% underestimation rates for atypical hyperplasia); repeat biopsy is warranted in such situations. When a discrepancy exists with imaging findings and for cases of atypical epithelial hyperplasia, surgical excision is imperative so as not to overlook or underestimate a malignant lesion. Controversy continues concerning the best approach for radial scars (sclerosing ductal lesions), papillary lesions, atypical lobular hyperplasia and lobular carcinoma in situ: determination of which benign anomalies can merely be followed-up remains a problem. Better awareness of the limitations of percutaneous tissue sampling procedures should lead to refinement of the indications for these techniques and improvement of patient selection and thereby reduce delays in accurate diagnosis.
Subject(s)
Biopsy/methods , Breast Diseases/pathology , Breast Neoplasms/pathology , Breast Diseases/diagnostic imaging , Breast Neoplasms/diagnostic imaging , Humans , RadiographyABSTRACT
OBJECTIVES: To investigate whether some aspects of patient or tumor characteristics influence the timing of local recurrence (LR) in breast cancer treated conservatively, and to assess the impact of the timing of LR on patient outcome. METHODS: A retrospective analysis was conducted on patients treated with conservative breast surgery followed by radiotherapy for breast carcinoma who developed LR. Out of 2,008 cases treated in our Institute between 1977 and 2002, 180 ipsilateral LR were observed. Of these, 46 LR were observed within 36 months after treatment, called early local recurrence (ELR), 44 developed between 37 and 60 months, called medium local recurrence (MLR), and 90 occurred after 60 months, called late local recurrence (LLR). Patient and tumor characteristics were analyzed in the 2 groups and compared. RESULTS: Primary tumors >20 mm were more frequently found in patients with ELR (31%) than in patients with LLR (17%, p = 0.047). Grade 3 tumors were more often encountered in patients with ELR than in patients with LLR (27 versus 7%, p = 0.0002). Patients with ELR more frequently had tumors with negative estrogen receptors than patients with LLR (37% versus 6%, p < 0.0001). There was no statistically significant difference in the axillary lymph node (LN) status between patients with ELR and those with LLR (35 and 23% of positive LN, respectively, p = 0.24). Tumor size, grade, LN status, hormone receptors and the timing of LR affected the specific survival (SS) from initial surgery. On multivariate analysis, only LN status and the timing of LR retained an independent prognostic value, with an odds ratio of 6.7 for ELR. After LR, the SS was also influenced by all of the above factors, and on multivariate analysis, LN status, hormone receptors and the timing of LR were independent predictors with an odds ratio of SS of 2.50 in case of ELR (p = 0.006). The 5-year SS after LR for ELR, MLR and LLR were 55.8, 74.8 and 79.5%, respectively. CONCLUSIONS: Unfavorable tumor characteristics such as big size, high grade, lack of hormone receptors, but not LN status, were associated with ELR. These findings suggest that patients with such aggressive tumor characteristics who do not recur early will have a lower risk of LLR than patients with more favorable factors.
Subject(s)
Adenocarcinoma/diagnosis , Breast Neoplasms/diagnosis , Mastectomy, Segmental , Neoplasm Recurrence, Local/diagnosis , Adenocarcinoma/classification , Adenocarcinoma/therapy , Breast Neoplasms/classification , Breast Neoplasms/therapy , Combined Modality Therapy , Female , Follow-Up Studies , Humans , Lymph Node Excision , Lymph Nodes/pathology , Middle Aged , Radiotherapy, Adjuvant , Retrospective Studies , Survival Rate , Time Factors , Treatment OutcomeABSTRACT
Disease staging of patients with breast cancer is based on the probability of metastatic disease, the reliability of complementary examinations, and therapeutic possibilities, evaluated on a cost/benefit basis. For regional disease staging, nodal status can be assessed by ultrasound, and the value of this approach can be optimized by imaging-guided biopsies. Ultrasound examination of nodes upstream of the sentinel node allows determination of the utility of this node and the indications for axillary resection. Work-up of metastatic spread is performed only after evaluation of risk factors for metastasis. Prior to therapy, and in the absence of any clinical warning signs for resectable tumors, there are no indications for imaging, which is reserved solely for locally advanced tumors.